The role of HGF/c-MET signaling pathway in lymphoma
Open Access
- 7 December 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 9 (1), 1-8
- https://doi.org/10.1186/s13045-016-0366-y
Abstract
Inappropriate activation of c-mesenchymal-epithelial transition (MET), the receptor tyrosine kinase (RTK) for hepatocyte growth factor (HGF), has been implicated in tumorigenesis and represented a promising therapeutic target for developing anticancer agents. In contrast to other solid tumors, there are limited data describing the functional role of HGF/c-MET signaling pathway in lymphoma. In the current review, we summarize recent findings about the expression, cellular mechanisms/functions, and therapeutic application of HGF/c-MET in different types of lymphoma, especially B cell lymphoma, T and NK cell lymphoma, and Hodgkin lymphoma. We also discuss the existing problems and future directions about studying the HGF/c-MET pathway in lymphoma cells.Keywords
Funding Information
- U.S. Department of Defense (CA140437)
This publication has 66 references indexed in Scilit:
- Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B‐cell lymphoma patients receiving R‐CHOPCancer Science, 2013
- Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell LymphomaPLOS ONE, 2013
- High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphomaDiagnostic Pathology, 2013
- CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphomaBlood Research, 2013
- Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphomaPublished by Ferrata Storti Foundation (Haematologica) ,2011
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cellsBiology of the Cell, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal disseminationInternational Journal of Cancer, 1996